Free Float 75,50 %
Shares Float 103,02 M
Shares Outstanding 136,46 M
LIDDS AB Share · SE0001958612 · A12DLG (XSTO) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of LIDDS AB
No Price
Share Float & Liquidity
Company Profile for LIDDS AB Share
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
Company Data
Name LIDDS AB
Company LIDDS AB (publ)
Website
https://www.liddspharma.com
Primary Exchange 
NASDAQ STOCKHOLM AB
NASDAQ STOCKHOLM AB
WKN A12DLG
ISIN SE0001958612
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mats Wiking
Country Sweden
Currency SEK
Employees 0,0 T
Address Virdings allé 32b, 754 50 Uppsala
IPO Date 2014-07-31
Stock Splits
| Date | Split |
|---|---|
| 17.01.2023 | 43:40 |
| 17.06.2020 | 81:80 |
| 10.06.2016 | 1053:1000 |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ STOCKHOLM AB | LIDDS.ST |
| Frankfurt | 5LD.F |
More Shares
Investors who hold LIDDS AB also have the following shares in their portfolio:
